Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 9/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.31 |
| ▸ | PPARG | P37231 | 10/20 | 0.31 |
| ▸ | PPARD | Q03181 | 7/20 | 0.31 |
| ▸ | REN | P00797 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6629197 | 1.00 | CTSS (0.34) | CTSSPPARATSHRPTPN1PTPN2 | |
| SCHEMBL6629199 | 1.00 | CTSS (0.34) | CTSSPPARATSHRPTPN1PTPN2 | |
| SCHEMBL6696433 | 0.86 | CTSS (0.42) | CTSS | |
| SCHEMBL6696429 | 0.86 | CTSS (0.42) | CTSS | |
| SCHEMBL6630136 | 0.85 | PPARA (0.33) | PPARATSHRPTPN1PTPN2PPARG | |
| SCHEMBL6632610 | 0.82 | PTPN1 (0.37) | CTSSPTPN1PTPN2PPARG | |
| SCHEMBL6062007 | 0.82 | PTPN1 (0.37) | CTSSPTPN1PTPN2PPARG | |
| SCHEMBL6062004 | 0.82 | PTPN1 (0.37) | CTSSPTPN1PTPN2PPARG | |
| SCHEMBL6630594 | 0.81 | CTSS (0.35) | CTSSPTPN1PTPN2RORC | |
| SCHEMBL6630597 | 0.81 | CTSS (0.35) | CTSSPTPN1PTPN2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | US | claimed |
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | US | disclosed |
| EP-1397340-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002098850-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | CTSS 1/4885PPARA 2585/4885TSHR 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.